Predictors and temporal trends of adjuvant aromatase inhibitor use in breast cancer.

@article{Svahn2009PredictorsAT,
  title={Predictors and temporal trends of adjuvant aromatase inhibitor use in breast cancer.},
  author={Tiffany H Svahn and Joyce C. Niland and Robert W. Carlson and Melissa E. Hughes and Rebecca Ottesen and Rachel Leigh Theriault and Stephen B. Edge and Anne F. Schott and Michael A. Bookman and Jane C. Weeks},
  journal={Journal of the National Comprehensive Cancer Network : JNCCN},
  year={2009},
  volume={7 2},
  pages={115-21}
}
After the first report of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial, adjuvant aromatase inhibitor use increased rapidly among National Comprehensive Cancer Network member institutions. Increased aromatase inhibitor use was associated with older age, vascular disease, overexpression of human epidermal growth factor receptor 2 (HER2), or more advanced stage, and substantial variation was seen among institutions. This article examines adjuvant endocrine therapy in… CONTINUE READING

From This Paper

Topics from this paper.
8 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-8 of 8 extracted citations

Similar Papers

Loading similar papers…